An in­tro­duc­tion to the End­points 100

I’m well in­to a new project at End­points that I’d like to tell you about. It’s called the End­points 100. (Up­date: List of ex­ec­u­tives is at the bot­tom of this ar­ti­cle.)

For the 14 or so years that I’ve cov­ered biotech on a dai­ly ba­sis, I’ve seen some dra­mat­ic shifts in biotechs’ ac­cess to cap­i­tal, at­ti­tudes about reg­u­la­to­ry con­di­tions for new drug ap­provals (on both sides of the At­lantic), views on gen­der di­ver­si­ty, along with a whole new fo­cus on drug pric­ing and the fu­ture of the in­dus­try. Usu­al­ly, these trends and at­ti­tudes are all tracked in ret­ro­spec­tive analy­ses.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.